The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > BUSINESS
BUSINESS
- Takeda to Merge Shire Japan in October
August 4, 2020
- JCR to Start Global Study of MPS I Med; Japan Launch Planned in September
August 4, 2020
- JCR to Boost Manufacturing Capacity for Temcell by 30%
August 4, 2020
- BMS Japan to Integrate Celgene Next Year, HQ Relocation Planned in H1 2022: Chief
August 3, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
- Pevonedistat Granted FDA’s Breakthrough Therapy Status for Higher-Risk MDS: Takeda
August 3, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
- Kyowa Kirin’s 1H Sales Up 4.2% Driven by Overseas Biz; Full-Year Guidance Down on Slack Nesp AG, COVID-19
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Teva Takeda Deal Aimed at Boosting Efficiency, Quality: Nichi-Iko Chief
July 31, 2020
- Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
- Nichi-Iko Pulls Out from Avigan Contract Manufacturing
July 31, 2020
- 28 Products from 10-Plus Firms Recalled due to Flawed Tests at Kyowa CritiCare
July 31, 2020
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Eisai Seeks Lenvima’s Label Expansion into Thymic Carcinoma
July 31, 2020
- Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…